FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386170876> ?p ?o ?g. }

• W4386170876 endingPage "e364507e" @default.
• W4386170876 startingPage "e364507e" @default.
• W4386170876 abstract "Topic: 12. Bone marrow failure syndromes incl. PNH - Clinical Background: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic) is a prototypic hemato-inflammatory disease juxtaposing for the first time rheumatologic and hematologic disorders under the aegis of a molecularly defined nosologic entity. Given its multifaceted clinical presentations, VEXAS represents a challenging masquerade syndrome and has elicited a wide medical interest. Indeed, this disorder lies at the interface between bone marrow failure syndromes, inflamm-aging and clonal hematopoiesis, displaying a tetrad of somatic mutations, morphologic features, inflammatory pathways and immune overshooting. UBA1 mutations constitute the genomic underpinnings of VEXAS, which oftentimes presents in association with MDS. Aims: Herein, we wanted to screenshot the current UBA1 diagnostic capabilities and clinical-genomic features of VEXAS in Italy, after 2 years from its discovery. Methods: This study was performed through a national survey, under the patronage of the Italian societies of experimental hematology (SIES) and rheumatology (SIR), mostly involved in the clinical management of VEXAS patients. Results: Overall, 13 out of 26 participating centers had available UBA1 genomic testing (Fig.1A). This consisted of either Sanger sequencing (50%), next-generation sequencing (NGS, 14%) or Droplet Digital PCR (ddPCR, 7%), whereas a combination of these was in use in 29% of the centers (Fig.1B). Over a median time of 13.7 months from UBA1 testing availability, the positivity rate achieved 11.5% (n=39 out of 337 total requests). Majority (72%) of VEXAS cases harbored threonine substitutions at the Met41 hotspot, followed by leucine and valine (14% each; Fig.1C). A complete set of information was available for 31 patients, all males. Median age at VEXAS diagnosis was 67 years (IQR=63-72). All patients had anemia (median hemoglobin 9.1 gr/dL, IQR=8.3-10.5) and macrocytosis (median MCV 106 fL, IQR=102-109.3). Bone marrow vacuoles were observed in myeloid (24%) and erythroid (4%) precursors, or both (72%) in all patients (Fig.1D). Recurrent polychondritis was the most common rheumatologic association, accounting for 52% of cases. Notably, 35% of patients also showed MGUS at serum protein electrophoresis evaluation. A concomitant MDS was registered in 68% of our patients, all falling into lower IPSS-R (scores <3.5) categories. When re-stratified according to IPSS-M, only 1 case was upstaged to the moderate high risk group while the others remained into lower-risk categories (negative IPSS-M values). Cytogenetics was normal in all patients apart from 3 MDS cases showing delY, t(12;16)(q13;q24) and trisomy8. DNMT3A was the most recurrently mutated gene (n=8), followed by TET2 (n=3) with a 34.9% median VAF (IQR, 25.75-38.5). At a median follow up of 8.8 months, 5 patients died because of infectious complications and 2 progressed to AML. Remarkably, one patient with ASXL1/SF3B1-mutant MDS evolved to AML upon acquisition of a RUNX1 mutation and is currently undergoing allogeneic HSCT after achievement of complete remission, whereas another underwent transplant with subsequent clinical and molecular reversion of VEXAS.Summary/Conclusion: We present here the first multidisciplinary Italian cartography of VEXAS, detailing genomic testing capabilities and peculiar features of this newly defined condition. Acute clinical acumen and multidisciplinary interactions are essential to identify VEXAS, which must be judiciously considered in male patients above 50 years of age presenting with a history of macrocytic anemia (with/without MDS) and autoinflammatory manifestations. Keywords: Somatic mutation, Bone marrow failure, MDS, VEXAS syndrome" @default.
• W4386170876 created "2023-08-26" @default.
• W4386170876 creator A5002237220 @default.
• W4386170876 creator A5017743088 @default.
• W4386170876 creator A5021292232 @default.
• W4386170876 creator A5021762787 @default.
• W4386170876 creator A5022330993 @default.
• W4386170876 creator A5023952807 @default.
• W4386170876 creator A5024646086 @default.
• W4386170876 creator A5026561327 @default.
• W4386170876 creator A5026855076 @default.
• W4386170876 creator A5027512145 @default.
• W4386170876 creator A5028850181 @default.
• W4386170876 creator A5031590759 @default.
• W4386170876 creator A5032774252 @default.
• W4386170876 creator A5033287794 @default.
• W4386170876 creator A5033655074 @default.
• W4386170876 creator A5034934678 @default.
• W4386170876 creator A5035626409 @default.
• W4386170876 creator A5038867568 @default.
• W4386170876 creator A5041794776 @default.
• W4386170876 creator A5044624520 @default.
• W4386170876 creator A5044869604 @default.
• W4386170876 creator A5047970410 @default.
• W4386170876 creator A5048532379 @default.
• W4386170876 creator A5050316774 @default.
• W4386170876 creator A5050985757 @default.
• W4386170876 creator A5052938541 @default.
• W4386170876 creator A5054065266 @default.
• W4386170876 creator A5057084037 @default.
• W4386170876 creator A5059441718 @default.
• W4386170876 creator A5065702528 @default.
• W4386170876 creator A5072253025 @default.
• W4386170876 creator A5073711573 @default.
• W4386170876 creator A5076198727 @default.
• W4386170876 creator A5080326198 @default.
• W4386170876 creator A5081205774 @default.
• W4386170876 creator A5082018333 @default.
• W4386170876 creator A5085155930 @default.
• W4386170876 creator A5088682221 @default.
• W4386170876 creator A5089760320 @default.
• W4386170876 creator A5092695967 @default.
• W4386170876 date "2023-08-01" @default.
• W4386170876 modified "2023-10-14" @default.
• W4386170876 title "P778: A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS: THE VEXAS ITALIAN EXPERIENCE" @default.
• W4386170876 doi "https://doi.org/10.1097/01.hs9.0000970016.36450.7e" @default.
• W4386170876 hasPublicationYear "2023" @default.
• W4386170876 type Work @default.
• W4386170876 citedByCount "0" @default.
• W4386170876 crossrefType "journal-article" @default.
• W4386170876 hasAuthorship W4386170876A5002237220 @default.
• W4386170876 hasAuthorship W4386170876A5017743088 @default.
• W4386170876 hasAuthorship W4386170876A5021292232 @default.
• W4386170876 hasAuthorship W4386170876A5021762787 @default.
• W4386170876 hasAuthorship W4386170876A5022330993 @default.
• W4386170876 hasAuthorship W4386170876A5023952807 @default.
• W4386170876 hasAuthorship W4386170876A5024646086 @default.
• W4386170876 hasAuthorship W4386170876A5026561327 @default.
• W4386170876 hasAuthorship W4386170876A5026855076 @default.
• W4386170876 hasAuthorship W4386170876A5027512145 @default.
• W4386170876 hasAuthorship W4386170876A5028850181 @default.
• W4386170876 hasAuthorship W4386170876A5031590759 @default.
• W4386170876 hasAuthorship W4386170876A5032774252 @default.
• W4386170876 hasAuthorship W4386170876A5033287794 @default.
• W4386170876 hasAuthorship W4386170876A5033655074 @default.
• W4386170876 hasAuthorship W4386170876A5034934678 @default.
• W4386170876 hasAuthorship W4386170876A5035626409 @default.
• W4386170876 hasAuthorship W4386170876A5038867568 @default.
• W4386170876 hasAuthorship W4386170876A5041794776 @default.
• W4386170876 hasAuthorship W4386170876A5044624520 @default.
• W4386170876 hasAuthorship W4386170876A5044869604 @default.
• W4386170876 hasAuthorship W4386170876A5047970410 @default.
• W4386170876 hasAuthorship W4386170876A5048532379 @default.
• W4386170876 hasAuthorship W4386170876A5050316774 @default.
• W4386170876 hasAuthorship W4386170876A5050985757 @default.
• W4386170876 hasAuthorship W4386170876A5052938541 @default.
• W4386170876 hasAuthorship W4386170876A5054065266 @default.
• W4386170876 hasAuthorship W4386170876A5057084037 @default.
• W4386170876 hasAuthorship W4386170876A5059441718 @default.
• W4386170876 hasAuthorship W4386170876A5065702528 @default.
• W4386170876 hasAuthorship W4386170876A5072253025 @default.
• W4386170876 hasAuthorship W4386170876A5073711573 @default.
• W4386170876 hasAuthorship W4386170876A5076198727 @default.
• W4386170876 hasAuthorship W4386170876A5080326198 @default.
• W4386170876 hasAuthorship W4386170876A5081205774 @default.
• W4386170876 hasAuthorship W4386170876A5082018333 @default.
• W4386170876 hasAuthorship W4386170876A5085155930 @default.
• W4386170876 hasAuthorship W4386170876A5088682221 @default.
• W4386170876 hasAuthorship W4386170876A5089760320 @default.
• W4386170876 hasAuthorship W4386170876A5092695967 @default.
• W4386170876 hasBestOaLocation W43861708761 @default.
• W4386170876 hasConcept C126322002 @default.
• W4386170876 hasConcept C2780007613 @default.
• W4386170876 hasConcept C54355233 @default.
• W4386170876 hasConcept C60644358 @default.
• W4386170876 hasConcept C71924100 @default.
• W4386170876 hasConcept C86803240 @default.
• W4386170876 hasConceptScore W4386170876C126322002 @default.

• next